Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

Large Outcome Studies Reported at AAOS Annual Meeting Support Longterm

Clinical Duration

CAMBRIDGE, Mass., March 10 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ), today announced findings from a large, multicenter, observational study that investigated the long-term durability of Carticel(R) (autologous cultured chondrocytes) in patients who had pain and functional impairment from defects in the articular cartilage of their knee. These findings revealed that almost 90 percent of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost 10 years. The data were presented at this week's American Academy of Orthopaedic Surgeons' (AAOS) annual meeting in San Fransisco.

"We knew that autologous chondrocyte implantation (ACI) worked for select patients, but did it last?" said Allen Anderson, MD, (Nashville, TN) a leading orthopaedic surgeon in the field of sports medicine who presented the data at the medical meeting. "These data suggest that the ACI technique not only works, but when it works, the results will last for a long time. Similar results of long term durability had been previously reported by Lars Peterson, M.D., but this multicenter experience suggests that sustainable results can be reproduced by others."

Study Results

The objectives of the study were to determine if a patient's improvement assessed at an early timepoint, defined as 1 to 5 years (mean 4.6 years) after Carticel implantation, could be sustained at a much later time point defined as 6 to 10 years (mean 9.2 years).

Seventy-two patients were enrolled from 35 different centers across the US. All patients enrolled h
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present its ... Get Up! Get Moving!®. This event promotes Hispanic family physical ... people of all ages and all sizes. The event, which ... at Kiest Park Recreation Center, 3080 S. Hampton Road, in ... 2007, we have partnered with National Alliance for Hispanic Health ...
(Date:9/2/2014)... September 02, 2014 West Hollywood ... complimentary consultations for Invisalign. This special offer includes a ... smiles to determine their candidacy for the procedure and ... Qualified patients may also be eligible for the Summer ... remainder of the month of August, patients who choose ...
(Date:9/2/2014)... 1, 2014 (HealthDay News) -- The quality of Americans, ... dietary disparity between the rich and poor is growing, ... most direct evidence to date that the extensive efforts ... quality are having some payoff, but it also indicates ... Dong Wang, a doctoral student in the department of ...
(Date:9/2/2014)... it comes to excess pounds and blood pressure, all fat ... The research found that belly fat -- the proverbial "spare ... more than overall body fat. It,s well known that ... wasn,t clear how the location of fat in the body ... Southwestern Medical Center in Dallas. Reporting Sept. 1 in ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 North ... America Resectoscopes Market Outlook to 2020? provides key ... The report provides value, in millions of US ... US dollars) within market segments –, ... (Disposable and Reusable) Electrodes and Bipolar (Disposable and ...
Breaking Medicine News(10 mins):Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4
... Legislation Introduced to Fund Lung Cancer ResearchBOSTON, Jan. ... Senator Susan Fargo (D-3rd Middlesex), the Senate Chair ... once again introducing comprehensive legislation that creates a ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )"Now is the time for positive ...
... (Nasdaq: ROCM ) today announced that Covidien ... litigation which Rochester Medical,filed on March 16, 2004 against ... L.P.; Novation, LLC; VHA Inc.; and Premier Purchasing,Partners L.P. ... of the settlement, Rochester Medical, represented by The,Lanier Law ...
... festival in Park,City, Utah, usually known for power lunches, will ... full-service fitness center, called,the "G Gym." Actors Eliza Dushku ... of the many celebrities to snatch up appointments with top,Hollywood ... or $1,000 for,charity, up to $20,000. , ...
... YORK, Jan. 15 On Tuesday, February 3, 2009, ... The Fifth Annual Beyond Beauty Gala to benefit The ... genetic research and awareness for Obsessive-Compulsive Disorder (OCD). ... evening,s event will be held at The Union League ...
... Package and House Vote to Expand Child Health InsuranceTUCSON, Ariz., ... Corporation (Nasdaq: PRSC ) today provided an update ... package being sought by President-elect Barack Obama as well as ... insurance. The economic stimulus package under discussion includes aid ...
... Roxane Laboratories, Inc.,announced today the approval of their ... 500mg, 750mg, 1000mg, and Oral Solution,100mg/mL. The product ... nationwide. , Roxane Laboratories, ... UCB, Inc.,s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) ...
Cached Medicine News:Health News:Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer 2Health News:Celebrities Stay Fit at First Ever Full-Service Luxury Gym at Film Festival in Park City, Utah 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 3Health News:Providence Service Corporation Provides Update on Potential Medicaid 2Health News:Providence Service Corporation Provides Update on Potential Medicaid 3Health News:Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution 2
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
Multi-frequency, Super High Density, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path....
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
This versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Medicine Products: